<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-117988</identifier>
<setSpec>1889-1837</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Renal effects of calcium antagonists</dc:title>
<dc:description xml:lang="en">Calcium antagonists are a family of antihypertensive drugs that have been widely shown to have high efficacy so they are widely used. Prevention of kidney function deterioration should be a priority in the course of the hypertensive patient. This is especially important due to the growing prevalence of chronic kidney failure in the general population. The data available on kidney function and treatment with calcium antagonists in hypertensive patients both with normal renal function as well as with established renal disease show that calcium antagonists are effective drugs that should be considered preferentially as single drug therapy as well as in combination with another drug with the capacity to inhibit the renin-angiotensin-aldosterone axis(AU)</dc:description>
<dc:creator>Ruilope, L. M</dc:creator>
<dc:creator>Garcia-Donaire, J. A</dc:creator>
<dc:creator>Cerezo, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los antagonistas del calcio son una familia de fármacos antihipertensivos que, ampliamente, han demostrado poseer una elevada eficacia, por lo que son empleados de forma generalizada. La prevención del deterioro de la función renal debe ser una prioridad en la evolución del paciente hipertenso, lo que resulta especialmente relevante debido a la creciente prevalencia de insuficiencia renal crónica en la población general. Los datos disponibles sobre función renal y tratamiento con antagonistas del calcio en pacientes hipertensos, tanto con función renal normal como con enfermedad renal establecida, demuestran que los antagonistas del calcio son fármacos efectivos que deben considerarse de forma preferente tanto en monoterapia como en combinación con otro fármaco con capacidad de inhibición del eje renina-angiotensina-aldosterona(AU)</dc:description>
<dc:source>Hipertens. riesgo vasc;26(3): 116-120, mayo-jun. 2009. tab</dc:source>
<dc:identifier>ibc-117988</dc:identifier>
<dc:title xml:lang="es">Efectos renales de los antagonistas del calcio</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d50495^s22036</dc:subject>
<dc:subject>^d6063^s22021</dc:subject>
<dc:subject>^d7152^s22057</dc:subject>
<dc:subject>^d12506^s22021</dc:subject>
<dc:subject>^d^s22080</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6590^s22021</dc:subject>
<dc:subject>^d23177^s22020</dc:subject>
<dc:subject>^d962^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200906</dc:date>
</metadata>
</record>
</ibecs-document>
